2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Genitourinary
1
Conditions
Vascular Calcification
1
Neoplasm Metastasis
1
Kidney Diseases
1
Hyperparathyroidism
1
Chronic Kidney Disease-Mineral and Bone Disorder
1
Bone Diseases
1
Interventions
Cisplatin
1519
Carboplatin
1420
Cyclophosphamide
1360
Gemcitabine
1235
Bevacizumab
1226
Paclitaxel
1211
Radiotherapy
1176
Docetaxel
1080
pembrolizumab
1028
Oxaliplatin
936
Capecitabine
901
Fluorouracil
833
Rituximab
729
Doxorubicin
683
Nivolumab
679
Dexamethasone
666
Etoposide
660
Irinotecan
622
Leucovorin
575
Pemetrexed
510
Drug Therapy
493
Cetuximab
483
Trastuzumab
469
Cytarabine
466
Magnetic Resonance Spectroscopy
458
Filgrastim
446
Prednisone
433
Lenalidomide
409
Specimen Handling
408
Temozolomide
400
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
etelcalcetide hydrochloride
×
Clear all
NCT03960437
2023-09-21
Parsabiv-MBD
Columbia University
Phase 2
Completed
22 enrolled
14 charts